Latvia Pharmaceuticals & Healthcare Report Q2 2013
Published by Business Monitor International
on Mar 4, 2013
, 92 pages
PDF - Download Now with 3 Quarterly Updates format - Delivered by download
BMI View: We view Latvia's pharmaceutical market as one of the least promising in the Emerging Europe region, from a longer-term point of view. Despite a largely favourable business and operating environment, pharmaceutical companies are looking at a market in which annual per capita expenditure on medicines is still below the US$200 mark. Strategies for cost-containment in public-sector healthcare, such as the possible use of joint procurement systems with its peer Baltic states, will also have an impact on this low-value market that serves a population of well under 2.5mn.